ReviewDialogues in clinical neuroscience2008
Incomplete response in late-life depression: getting to remission.
Review in Dialogues in clinical neuroscience, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 78 citations in OpenAlex.
- Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome.JAMA network open · 2022Trial
- Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.International journal of geriatric psychiatry · 2018Trial
- The role of late life depressive symptoms on the trajectories of insomnia symptoms during antidepressant treatment.Journal of psychiatric research · 2018Trial
- Depression and Suicidal Ideation During Two Psychosocial Treatments in Older Adults with Major Depression and Dementia.Journal of Alzheimer's disease : JAD · 2015Trial
- Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2011Trial
- Home-delivered problem adaptation therapy (PATH) for depressed, cognitively impaired, disabled elders: A preliminary study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2010Trial
- Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Anti-Amyloid Drugs for Alzheimer's Disease: Considering the Role of Depression.Neuro-degenerative diseases · 2025Article
- Age as a moderating factor of treatment resistance in depression.European psychiatry : the journal of the Association of European Psychiatrists · 2023Article
- Impact of Tai Chi as an adjunct treatment on brain connectivity in geriatric depression.Journal of affective disorders · 2022Article
- Effects of Mindfulness-Based Cognitive Therapy on Peripheral Markers of Stress and Inflammation in Older-Adults With Depression and Anxiety: A Parallel Analysis of a Randomized Controlled Trial.Frontiers in psychiatry · 2021Article
- Illness narratives and preferences for treatment among older veterans living with treatment-resistant depression and insomnia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists · 2020Article
- Depression, cognitive, and functional outcomes of Problem Adaptation Therapy (PATH) in older adults with major depression and mild cognitive deficits.International psychogeriatrics · 2020Article
- Metformin Improves the Depression Symptoms of Women with Polycystic Ovary Syndrome in a Lifestyle Modification Program.Patient preference and adherence · 2020Article
- Brief behavioral treatment for insomnia in older adults with late-life treatment-resistant depression and insomnia: a pilot study.Sleep and biological rhythms · 2019Article
- Effects of Integrated Telehealth-Delivered Cognitive-Behavioral Therapy for Depression and Insomnia in Rural Older Adults.Journal of psychotherapy integration · 2018Article
- The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression.Contemporary clinical trials · 2018Article
- Mindfulness-Based Cognitive Therapy in the Treatment of Late-Life Anxiety and Depression-a Pilot Study.Canadian geriatrics journal : CGJ · 2016Article
- Directions for Effectiveness Research to Improve Health Services for Late-Life Depression in the United States.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2016Review
- Comparison of the Antidepressant-Like Effects of Estradiol and That of Selective Serotonin Reuptake Inhibitors in Middle-Aged Ovariectomized Rats.Frontiers in aging neuroscience · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Incomplete response in the treatment of late-life depression is a large public health challenge: at least 50% of older people fail to respond adequately to first-line antidepressant pharmacotherapy, even under optimal treatment conditions. Treatment-resistant late-life depression (TRLLD) increases risk for early relapse, undermines adherence to treatment for coexisting medical disorders, amplifies disability and cognitive impairment, imposes greater burden on family caregivers, and increases the risk for early mortality, including suicide. Getting to and sustaining remission is the primary goal of treatment, yet there is a paucity of empirical data on how best to manage TRLLD. A pilot study by our group on aripiprazole augmentation in 24 incomplete responders to sequential SSRI and SRNI pharmacotherapy found that 50% remitted over 12 weeks with the addition of aripiprazole, and that remission was sustained in all participants during 6 months of continuation treatment. In addition to controlled assessment, evidence is needed to support personalized treatment by testing the moderating role of clinical (e.g., comorbid anxiety, medical burden, and executive impairment) and genetic (eg, selected polymorphisms in serotonin, norepinephrine, and dopamine genes) variables, while also controlling for variability in drug exposure. Such studies may advance us toward the goal of personalized treatment in late-life depression.
Indexed as
Identifiers
19170399PMC3181898W52098624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.